This week in Clipboard Health’s Nursing News round-up …
United States May Begin Distributing COVID-19 Vaccine as Early as Friday
An advisor from the U.S. Food and Drug Administration said that the first vaccines may be given to Americans as early as Friday.
The FDA panel responsible for reviewing each vaccine will meet on Thursday to assess the Pfizer vaccine’s trial data. If all goes well, the panel will advise the FDA on approval, and the vaccine can be authorized for distribution within 24 hours.
Find out when you might be eligible for the vaccine.
Gene-Editing May Be One-Time Treatment, Cure for Sickle Cell Disease
During the American Society of Hematology conference over the weekend, scientists presented early results of a new one-time treatment for sickle cell disease that involves editing the DNA in red blood cells using the CRISPR tool.
The study, which involves 10 patients with sickle cell disease, is still ongoing, but the patients are now several months out from the initial treatment, and all report no pain and no longer have a need for regular blood transfusions.
COVID-19 Passed Heart Disease to Become Leading Cause of Death in the U.S.
The Institute for Health Metrics and Evaluation reported last week that COVID-19 has become the leading cause of death in the United States this past week, surpassing heart disease.
CDC Revises Quarantine Guidance Following COVID-19 Exposure
The U.S. Centers for Disease Control and Prevention revised its quarantine recommendations for those who are exposed to the coronavirus. The organization now recommends that you quarantine for seven days if you have a negative COVID-19 test and 10 days if you don’t get a test, so long as you don’t show any symptoms.
These two options are meant as alternatives to the normal 14-day quarantine recommendations, which the CDC still encourages people to follow as much as possible.
CDC Approves Recommendation for Health Care Workers, Long-Term Care Residents to be First for Vaccines
The U.S. Centers for Disease Control and Prevention approved the recommendation from an advisory panel to put health care workers and residents of long-term health care facilities as the first people to get COVID-19 vaccines.
Medical Studies Round-Up
Here’s a brief round-up of recent medical studies and their findings for you to stay up-to-date with the ever-evolving field of medical research.
- A new study outlines potential technology that can use a smartphone camera and a CRISPR-based COVID-19 test to provide an accurate result within 30 minutes or less.
- Researchers at the Washington University School of Medicine in St. Louis identified a new form of an Alzheimer’s protein that can show which stage of the disease a patient is in. The discovery can greatly benefit the development of treatments for the disease.
- Studies show that Black patients are noticeably much more likely to test positive for COVID-19, but a new study shows that once Black patients with COVID-19 are hospitalized, they do as well or even better than white patients in terms of overall disease severity and health outcome.
Race for the Vaccine: Coronavirus Vaccine Updates
Here are the most recent updates from the past week on COVID-19 vaccine development.
Last week, Britain became the first country to approve the Pfizer and BioNTech coronavirus vaccine. Distribution in the country begins this week.
Moderna anticipates emergency use approval for its vaccine within one to three days after the U.S. Food and Drug Administration panel meets to assess the vaccine’s trial data on December 17.
The World Health Organization stated during its Monday briefing that it does not anticipate COVID-19 vaccines to become a mandatory vaccine in any country.
After confusing trial data where some British volunteers inadvertently received half vaccine doses instead of full ones, one of the main scientists overseeing the U.S. AstraZeneca trials stated that the U.S. trials will clear up any confusion that previous data suggested. The company expects data from the U.S. trials in late January.
Inovio gave its first dose to its first trial volunteer to begin its Phase 2 trials, which aims to enroll 400 volunteers over the age of 18 years old.